Axxess Pharma, Inc. Nears Completion of Exclusive License Agreement to Globally Market and Distribute High Potency Vitamin D-3 t
June 30 2010 - 8:30AM
Marketwired
Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company
specializing in the marketing and distribution of both prescription
and non-prescription medical products, is pleased to announce they
are in the final stages of signing an exclusive license agreement
to market and distribute a high potency, highly concentrated
vitamin D-3 capsule. This vitamin can be taken once a week in
adjunct with calcium to help reduce bone loss and joint pain.
Axxess Pharma's license agreement will allow the Company the
right to market the vitamin under their brand name in Canada and
select countries worldwide. The vitamin is currently being sold in
the United States.
Vitamin D deficiency has been known to contribute to
musculoskeletal symptoms and bone loss in women with breast cancer.
The high potency, once a week capsule will help reduce these costly
and painful symptoms while allowing patients and individuals the
ability to focus on their daily life. This capsule will also help
reduce fatigue, stiffness, joint pain and impaired muscle strength
associated when individuals take aromatase inhibitors.
"We look forward to completing this exclusive license agreement
and further expanding our line of prescription and non-prescription
drugs worldwide. We anticipate signing the exclusive license
agreement within 2 weeks," stated Gerald Sequeira,
President/CEO.
For more information, please contact Investor Relations at (973)
351-3868.
About Axxess Pharma, Inc.: Axxess Pharma, Inc. is a specialty
pharmaceutical company that focuses on the marketing of
dermatological, therapeutic nutritionals, pain management and
diagnostic products in Canada and abroad since 1997. Axxess owns 22
established pharmaceutical prescription products that have proven
sales in Canada and internationally. The company has an experienced
management team and field sales force to market products nationally
to hospitals and retail pharmacies as well as specialized practice
areas including Dermatology and Nephrology, Neurology and
Urology.
Safe Harbor Statements about the Company's future expectations
and all other statements in this press release other than
historical facts, are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934, and as that term is defined
in the Private Securities Litigation Reform Act of 1995. The
Company intends that such forward-looking statements be subject to
the safe harbors created thereby. The above information contains
information relating to the Company that is based on the beliefs of
the Company and/or its management, as well as assumptions made by
any information currently available to the Company or its
management. When used in this document, the words "anticipate,"
"estimate," "expect," "intend," "plans," "projects," and similar
expressions, as they relate to the Company or its management, are
intended to identify forward-looking statements. Such statements
reflect the current view of the Company regarding future events and
are subject to certain risks, uncertainties and assumptions,
including the risks and uncertainties noted. Should one or more of
these risks or uncertainties materialize, or should underlying
assumptions prove to be incorrect, actual results may vary
materially from those described herein as anticipated, believed,
estimated, expected, intended or projected. In each instance,
forward-looking information should be considered in light of the
accompanying meaningful cautionary statements herein. Factors that
could cause results to differ include, but are not limited to,
successful performance of internal plans, the impact of competitive
services and pricing and general economic risks and
uncertainties.
Contact: Taylor Capitol, Inc. Investor Relations Stephen Taylor
973-351-3868 Email Contact
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Sep 2024 to Oct 2024
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Oct 2023 to Oct 2024